Experience Since MELD Implementation: How Does the New System Deliver?

Table 1

Standard MELD exceptions in Germany and their adjusted MELD score or adjusted 3-months-mortality, respectively [3].

Disease	Initial match MELD/adjusted 3-month mortality
Hepatocellular carcinoma (HCC)	15%
Hepatoblastoma	MELD 30
Polycystic liver disease	10%
Hyperoxaluria type 1	10%
Persisting dysfunction following OLT; (including “small-for-size”)	Current lab MELD  plus; 20%
Cystic fibrosis	10%
Familial amyloid polyneuropathy (FAP)	15%
Hepatopulmonary syndrome	15%
Portopulmonary hypertension (POPH)	25%
Urea cycle disorders	MELD 30
Morbus Osler	15%
Hepatic epithelioid hemangioendothelioma (HEHE)	15%
Biliary sepsis/secondary sclerosing cholangitis (SSC)	Current lab MELD  plus; 30%
Primary sclerosing cholangitis (PSC)	15%
Cholangiocarcinoma	10%